Co-Stars Version 1.0 [COVID-19] [UPH]
Research type
Research Study
Full title
COVID-19 Staff Testing of Antibody Responses Study (CO-STARS)
IRAS ID
282713
Contact name
Louis Grandjean
Contact email
Sponsor organisation
Great Ormond Street Hospital nHS Trust
Clinicaltrials.gov Identifier
20CB17, Great Ormond Street Hospital Reference Number
Duration of Study in the UK
6 years, 3 months, 1 days
Research summary
A total of 250 healthcare workers are currently off sick with symptoms of SARS-CoV-2 infection (COVID-19) while 99 additional members of staff have been diagnosed with confirmed SARS-CoV-2 at Great Ormond Street Hospital. As a consequence, all routine surgery, out-patient activity and day cases have been postponed or cancelled altogether. It is therefore critical for us to understand whether or not this disease will continue to threaten staff health or whether natural infection will give rise to long lasting immunity. This study will perform prospective repeated serological antibody testing on a cohort of at least 1000 healthcare workers at Great Ormond Street Hospital. Within this cohort, a subset of 150-250 staff members with confirmed (PCR positive) SARS-CoV-2 disease will be followed with intensive monthly testing for 6 months to determine whether antibody levels in the blood are maintained or decrease during this time. All 1000 recruited healthcare workers will be followed 6-monthly with repeated serological antibody testing for a total of 6 years. In addition to repeated serological testing, recruited healthcare workers will have ongoing access to our staff testing program (should they have any further symptoms) and all will be asked to complete a detailed symptom and electronic questionnaire prior to each appointment. This will enable us to determine the attack rate (percentage of healthcare workers infected) and incidence (the rate of new occurrences of the disease) of SARS-CoV-2 infection amongst healthcare workers without protective antibodies and compare this to the rate of reinfection among those with the presence of SARS-CoV-2 antibodies.
REC name
N/A
REC reference
N/A